HOW IS CHEMOTHERAPY USED AT THE END OF LIFE IN A SECONDARY HOSPITAL?
5PSQ-152
EFFECTIVENESS AND SAFETY OF ERENUMAB IN MIGRAINE PROPHYLAXIS
5PSQ-151
OPTIMIZATION OF THE SUBCUTANEOUS ADMINISTRATION OF DARATUMUMAB
5PSQ-139
ANTICHOLINERGIC RISK EVALUATION IN HOSPITALISED PATIENTS
5PSQ-138
IMPACT OF HIGH TEMPERATURE, SHAKING AND LIGHT ON QUALITY OF THE THERAPEUTIC PEPTIDE TEDUGLUTIDE (REVESTIVE®) EVALUATED BY LC/MS/MS (ORBITRAP) PEPTIDE MAPPING ANALYSIS AND STRESS
5PSQ-137
MEDICATION ERRORS RELATING TO ISOAPPEARANCES IN THE EMERGENCY ROOM
5PSQ-116
Medication-related follow-up of older patients after hospital discharge: a multicentre retrospective chart review
5PSQ-104
VOLUNTARY ELECTRONIC REPORTING OF MEDICATION ERRORS AND ADVERSE DRUGS EVENTS DURING THE FIRST YEAR OF THE COVID-19 PANDEMIC
5PSQ-101
MEDICATION ERRORS IN UNIT-DOSE DRUG DISTRIBUTION SYSTEM: QUALITY CONTROL
5PSQ-092
TREATMENT OF METASTATIC HER2+ BREAST CANCER: USE OF TRASTUZUMAB BIOSIMILARS IN COMBINATION WITH PERTUZUMAB
5PSQ-091
DALBAVANCIN ADMINISTRATION IN OUTPATIENTS TO REDUCE HOSPITAL STAY IN SELECTED PATIENTS
5PSQ-036
IMPROVEMENT IN POSTOPERATIVE PAIN CONTROL BY THE INTRODUCTION OF ELASTOMETRIC LOCAL ANAESTHESIC LEVOBUPIVACAINE PUMPS IN PATIENTS UNDERGOING ARTHROPLASTY
5PSQ-076
EVALUATION AND MONITORING OF BIOCHEMICAL PARAMETERS IN PATIENTS ON PARENTERAL NUTRITION
5PSQ-024
Effectiveness and safety of durvalumab in the treatment of unresectable locally advanced non small cell lung cancer (LANSCLC)
5PSQ-009
Patient Safety and Medication Safety Culture in a Hospital Pharmacy Department: A Mixed Methods Study
